Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.24.3
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 4,702 8,256 15,560 27,649
General and administrative 2,263 3,425 8,510 12,580
Operating expenses 6,965 11,681 24,070 40,229
Other income/(expense):        
Interest income 12 232 226 980
Foreign exchange income/(loss) 0 2 (1) (3)
Total other income 12 234 225 977
Net loss (6,953) (11,447) (23,845) (39,252)
Other comprehensive loss:        
Unrealized (loss) gain on available-for-sale securities 0 0 0 3
Total comprehensive loss $ (6,953) $ (11,447) $ (23,845) $ (39,249)
Basic loss per common share (in dollars per share) $ (0.37) $ (1.76) $ (1.48) $ (6.14)
Diluted loss per common share (in dollars per share) $ (0.37) $ (1.76) $ (1.48) $ (6.14)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 18,560 6,495 16,107 6,391
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares) 18,560 6,495 16,107 6,391